Celadon Pharmaceuticals Plc has received approval from the National Health Service ("NHS") Research Ethics Committee to roll-out its non-cancer chronic pain clinical trial for up to 5,000 patients (the "Trial"). The Company previously held conditional approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") for the Trial, however before formally commencing the Trial, the NHS's Ethics Committee requested an initial Feasibility Study to be conducted over a three-month period. The results of the Feasibility Study were submitted for review on 30 December 2022 (as announced by the Company) and indicatedpositive outcomes for quality of life, pain and sleep, as well as the reduction of opioid usage.

As an approved Trial, it is believed to be the only one of its kind in the UK, and is designed tocreate adata set that will support doctors' prescriptions of cannabis-based medicines, and in time enable potential reimbursement by the NHS and insurance companies. It also enables General Practitioners to prescribe the medicine to patientsin addition to specialist doctors, and organizations such as charities can advertise recruitment for the Trial. The Company believes this to be a major advance in enabling much wider access for patients, ultimately leading to the opening up of the UK market for cannabis-based medicines.

The Company is working with its partners to finalise the plan for the optimal and timely roll-out of the Trial.